TrialClinical and translational science2023

First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.

Ian M Catlett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.